Lataneau (Latanoprost)

Latanoprost binds to prostaglandin F2α receptors in the eye’s ciliary body, stimulating the uveoscleral pathway. This increases the outflow of aqueous humor, which reduces intra‑ocular pressure and lessens the risk of glaucoma‑related vision loss.

The prescribed dose of Lataneau is determined by the treating clinician. Typically, one drop is instilled in the affected eye(s) once daily, usually in the evening, but the exact regimen should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare professional before using Lataneau.

To order Lataneau, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with beta‑blocker eye drops such as timolol, latanoprost often provides greater IOP reduction with once‑daily dosing and a different side‑effect profile. It is frequently used as first‑line therapy or in combination with other agents when additional pressure lowering is needed.

Lataneau should be stored at temperatures below 25 °C, in its original container, protected from light and moisture. Do not freeze the product. Keep the bottle tightly closed when not in use and discard any solution that appears discolored or contaminated.

Lataneau is supplied as sterile eye drops. Tilt the head back, pull down the lower eyelid to create a pocket, and instill one drop into the conjunctival sac. Close the eye gently for a few seconds, avoid blinking excessively, and wash hands before and after use.

Serious adverse events, although rare, include severe eye inflammation (uveitis or iritis), macular edema, allergic reactions such as swelling or difficulty breathing, and ocular infections. Patients should seek immediate medical attention if they experience any of these symptoms.

Lataneau is contraindicated in individuals with active ocular infections or inflammation, those who are hypersensitive to latanoprost or any component of the formulation, and patients using other prostaglandin analog eye drops concurrently. Consultation with a healthcare provider is essential before initiating therapy.